Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CHKA | P35790 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.45 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28811478 | 0.96 | CA2 (0.54) | CA2CHKACA12CA1CA9 | |
| SCHEMBL23778315 | 0.95 | CA2 (0.50) | CA2CHKACA12CA1CA9 | |
| SCHEMBL27887523 | 0.93 | CA2 (0.61) | CA2CHKACA12CA1CA9 | |
| SCHEMBL6961568 | 0.90 | — | — | |
| SCHEMBL15319 | 0.90 | — | — | |
| SCHEMBL17100538 | 0.90 | CA2 (0.56) | CA2CHKACA12CA1CA9 | |
| Hydrochloric Acid SCHEMBL18116041 | 0.87 | CA2 (0.54) | CA2CHKACA12CA1CA9 | |
| Hydrochloric Acid SCHEMBL125486 | 0.87 | CA2 (0.54) | CA2CHKACA12CA1CA9 | |
| Water SCHEMBL11193463 | 0.87 | CA2 (0.54) | CA2CHKACA12CA1CA9 | |
| Water SCHEMBL10607939 | 0.87 | CA2 (0.54) | CA2CHKACA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951689-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007056046-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-05-18 | — | — | WO | claimed |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025245046-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12331035-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-06-17 | — | — | US | disclosed |
| WO-2025106910-A1 | DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR | FLARE THERAPEUTICS INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2024256569-A1 | NOVEL CDK DEGRADERS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2024-12-19 | — | — | WO | disclosed |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050043325-A1 | Novel pharmaceuticals | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2004096810-A1 | 5,7-DIAMINOPYRAZOLO`4,3-D!PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | WEINSTOCK, STEVEN F. | 2004-01-01 | — | — | US | disclosed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| US-6492355-B1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| EP-0703908-A1 | ANALGESIC DIBENZOXAZEPINES AND DIBENZOTHIAZEPINES | G.D. SEARLE & CO. (US) | 1996-04-03 | — | — | EP | disclosed |
| WO-1994029286-A1 | ANALGESIC DIBENZOXAZEPINES AND DIBENZOTHIAZEPINES | G.D. SEARLE & CO. (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, GLP1R | CA2 4604/4885CHKA 2011/4885CA12 4840/4885 |
| US-20050043325-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | CA2 2687/4885CHKA 2058/4885CA12 1003/4885 |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | CA2 1837/4885CHKA 2875/4885CA12 3742/4885 |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | CA2 4629/4885CHKA 1962/4885CA12 4328/4885 |
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, FFAR3 | CA2 3648/4885CHKA 1022/4885CA12 4486/4885 |
| US-12331035-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | CA2 4652/4885CHKA 2036/4885CA12 4697/4885 |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | CA2 4203/4885CHKA 2167/4885CA12 4358/4885 |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | CA2 4629/4885CHKA 1962/4885CA12 4328/4885 |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | CA2 4373/4885CHKA 336/4885CA12 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.